Katherine A. High

39.2k total citations · 10 hit papers
271 papers, 20.3k citations indexed

About

Katherine A. High is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Katherine A. High has authored 271 papers receiving a total of 20.3k indexed citations (citations by other indexed papers that have themselves been cited), including 189 papers in Genetics, 162 papers in Molecular Biology and 95 papers in Oncology. Recurrent topics in Katherine A. High's work include Virus-based gene therapy research (185 papers), CAR-T cell therapy research (95 papers) and Hemophilia Treatment and Research (71 papers). Katherine A. High is often cited by papers focused on Virus-based gene therapy research (185 papers), CAR-T cell therapy research (95 papers) and Hemophilia Treatment and Research (71 papers). Katherine A. High collaborates with scholars based in United States, Canada and Italy. Katherine A. High's co-authors include Federico Mingozzi, Roland W. Herzog, Valder R. Arruda, Xavier M. Anguela, Linda B. Couto, Shangzhen Zhou, Maria Grazia Roncarolo, Cynthia E. Dunbar, Daniel J. Hui and J. Nathan Hagstrom and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Katherine A. High

264 papers receiving 19.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gene therapy comes of age

2018 993 citations Cynthia E. Dunbar, Katherine A. High et al. Science profile →
Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector

2000 782 citations Mark A. Kay, Linda B. Couto et al. profile →
Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges

2011 728 citations Federico Mingozzi, Katherine A. High profile →
Immune responses to AAV vectors: overcoming barriers to successful gene therapy

2013 676 citations Federico Mingozzi, Katherine A. High Blood profile →
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B

2003 578 citations Roland W. Herzog, Linda B. Couto et al. Blood profile →
CD8+ T-cell responses to adeno-associated virus capsid in humans

2007 573 citations Federico Mingozzi, Daniel J. Hui et al. profile →
Recombinant adeno-associated virus for muscle directed gene therapy

1997 564 citations Katherine A. High et al. profile →
Gene Therapy

2019 370 citations Katherine A. High et al. profile →
Entering the Modern Era of Gene Therapy

2018 347 citations Xavier M. Anguela, Katherine A. High profile →
Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation–Associated Inherited Retinal Dystrophy

2019 276 citations Albert M. Maguire, Stephen R. Russell et al. profile →

Peers

Countries citing papers authored by Katherine A. High

Since Specialization

Citations

This map shows the geographic impact of Katherine A. High's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine A. High with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine A. High more than expected).

Fields of papers citing papers by Katherine A. High

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine A. High. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine A. High. The network helps show where Katherine A. High may publish in the future.

Co-authorship network of co-authors of Katherine A. High

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine A. High. A scholar is included among the top collaborators of Katherine A. High based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine A. High. Katherine A. High is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Roadmap for direct and indirect translation of optogenetics into discoveries and therapies for humans 2025 ·Nature Neuroscience ·Christian Lüscher, Valentina Emiliani, Nita A. Farahany, Aryn H. Gittis, Viviana Gradinaru, Katherine A. High, Botond Roska, José‐Alain Sahel, Ofer Yizhar, Hongkui Zeng, Karl Deisseroth	0
2	Gene therapy for hemophilia – From basic science to first approvals of “one-and-done” therapies 2025 ·Molecular Therapy ·Roland W. Herzog, Radosław Kaczmarek, Katherine A. High	5
3	Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A 2021 ·Molecular Therapy — Methods & Clinical Development ·(unknown), Sean M. Armour, Raffaella Toso, (unknown), Robert J. Davidson, Giang N. Nguyen, (unknown), (unknown), (unknown), (unknown), Marco Crosariol, Yuhuan Wang, Chuansong Wang, Katherine A. High, Denise E. Sabatino, Xavier M. Anguela	13
4	Long-term Effect of Voretigene Neparvovec on the Full-Field Light Sensitivity Threshold Test of Patients with RPE65 Mutation-Associated Inherited Retinal Dystrophy – Post Hoc Analysis of Phase I trial data 2019 ·Investigative Ophthalmology & Visual Science ·Daniel C. Chung, Kelly C. Lee, Kathleen Z. Reape, Katherine A. High, (unknown), (unknown)	7
5	Gene therapy comes of age breakdown → 2018 ·Science ·Cynthia E. Dunbar, Katherine A. High, J. Keith Joung, Donald B. Kohn, Keiya Ozawa, Michel Sadelain	993
6	Correlation of multi-luminance mobility testing with visual function tests in a phase 3 trial of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease 2017 ·Investigative Ophthalmology & Visual Science ·Daniel C. Chung, Stephen R. Russell, Jean Bennett, Albert M. Maguire, Jennifer Wellman, Zi‐Fan Yu, Amy Tillman, Katherine A. High	3
7	Year 2 results for a phase 3 trial of voretigene neparvovec in biallelic RPE65-mediated inherited retinal disease 2017 ·Investigative Ophthalmology & Visual Science ·Stephen R. Russell, Jean Bennett, Jennifer Wellman, Daniel C. Chung, Katherine A. High, Zi‐Fan Yu, Amy Tillman, Albert M. Maguire	6
8	Translational Data from Adeno-Associated Virus-Mediated Gene Therapy of Hemophilia B in Dogs 2015 ·PubMed ·Timothy C. Nichols, (unknown), Valder R. Arruda, Hansell H. Stedman, Mark A. Kay, Katherine A. High	27
9	Translational Data from AAV-Mediated Gene Therapy of Hemophilia B in Dogs 2014 ·Timothy C. Nichols, (unknown), Valder R. Arruda, Hansell H. Stedman, Mark A. Kay, Katherine A. High	4
10	Gene therapy for hemophilia 2014 ·The biomedical & life sciences collection. ·Katherine A. High	4
11	Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer 2012 ·Blood ·George Buchlis, Gregory M. Podsakoff, (unknown), (unknown), Alan W. Flake, Federico Mingozzi, Katherine A. High	179
12	Assessing the potential for AAV vector genotoxicity in a murine model 2010 ·Blood ·Hojun Li, Nirav Malani, (unknown), Alexander Schlachterman, (unknown), (unknown), Rachel Shah, Valder R. Arruda, Federico Mingozzi, J. Fraser Wright, Frederic D. Bushman, Katherine A. High	190
13	AAV-1–mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells 2009 ·Blood ·Federico Mingozzi, J. J. M. Meulenberg, Daniel J. Hui, Etiena Basner‐Tschakarjan, Nicole C. Hasbrouck, Shyrie Edmonson, Natalie A. Hutnick, Michael R. Betts, John J.P. Kastelein, Erik S.G. Stroes, Katherine A. High	227
14	Impact of the Underlying Mutation and the Route of Vector Administration on Immune Responses to Factor IX in Gene Therapy for Hemophilia B 2009 ·Molecular Therapy ·Ou Cao, Brad E. Hoffman, Babak Moghimi, Sushrusha Nayak, Mario Cooper, Shangzhen Zhou, Hildegund C.J. Ertl, Katherine A. High, Roland W. Herzog	84
15	The Jeremiah Metzger Lecture: gene therapy for inherited disorders: from Christmas disease to Leber's amaurosis. 2009 ·PubMed ·Katherine A. High	3
16	Intramuscular Administration of AAV1-Lipoprotein Lipase ^S447X Lowers Triglycerides in Lipoprotein Lipase–Deficient Patients 2008 ·Arteriosclerosis Thrombosis and Vascular Biology ·Erik S.G. Stroes, Melchior C. Nierman, J. J. M. Meulenberg, Remco Franssen, Jaap Twisk, C. P. Henny, Mario Maas, Aeilko H. Zwinderman, Colin J.D. Ross, Eleonora Aronica, Katherine A. High, Marcel M. Levi, Michael R. Hayden, John J.P. Kastelein, Jan Albert Kuivenhoven	145
17	Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy 2006 ·Blood ·Haiyan Jiang, Linda B. Couto, Susannah Patarroyo‐White, Tongyao Liu, Dea Nagy, Joseph Vargas, Shangzhen Zhou, Ciaran D. Scallan, Jürg M. Sommer, Sharmila Vijay, Federico Mingozzi, Katherine A. High, Glenn F. Pierce	276
18	Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII 2004 ·Journal of Clinical Investigation ·Paris Margaritis, Valder R. Arruda, (unknown), Rodney M. Camire, Alexander Schlachterman, Katherine A. High	3
19	Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII 2004 ·Journal of Clinical Investigation ·Paris Margaritis, Valder R. Arruda, (unknown), Rodney M. Camire, Alexander Schlachterman, Katherine A. High	55
20	Homocysteine and Prothrombin Fragment 1+2 Levels in Patients with Veno-Occlusive Disease after Stem Cell Transplantation 2003 ·Journal of Hematotherapy & Stem Cell Research ·John F. Gerecitano, Clarissa Mathias, Rosemarie Mick, Kathleen M. Duffy, Selina M. Luger, Edward A. Stadtmauer, Stephen J. Schuster, Donald E. Tsai, Sunita D. Nasta, Jesse A. Berlin, (unknown), Katherine A. High, David L. Porter	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact